# US 2022/0008565 A1 · Enhanced in Vivo Targeting of Site-Specific Drugs

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0008565 A1
- Document ID: US20220008565A1
- Status: Published application
- Kind: A1
- Application number: 17/484,727
- Filed: 2021-09-24
- Published: 2022-01-13
- Earliest claimed: 2011-07-08
- Applicants: Advanced Accelerator Applications USA, Inc.
- Inventors: Theodosia Maina-Nock; Berthold Artur Nock; Marion de Jong Hendriks
- Web page: https://patentgrep.com/patent/US20220008565A1

## CPC

- A61K 51/085: {the peptide being neurotensin}
- A61K 31/265: of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
- A61K 31/7028: Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K 31/7056: containing five-membered rings with nitrogen as a ring hetero atom
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 51/08: Peptides, e.g. proteins {, carriers being peptides, polyamino acids, proteins}
- A61K 51/083: {the peptide being octreotide or a somatostatin-receptor-binding peptide}
- A61K 51/086: {the peptide being alphaMSH, alpha melanocyte stimulating hormone}
- A61K 51/088: {conjugates with carriers being peptides, polyamino acids or proteins (antibodies A61K51/10)}
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a compound that inhibits the activity of a degrading enzyme for use in combination with a therapeutic or diagnostic compound, preferably a moiety conjugated peptide, in the diagnosis and/or treatment of a disease, in particular cancer, to enhance targeting of the therapeutic or diagnostic compound to the disease site.

## Claims

### Claim at position 1

1-40. (canceled)

### Claim 41

A composition comprising a radiolabeled biodegradable peptide analog and a neutral endopeptidase (NEP) inhibitor,
wherein the peptide-portion of the radiolabeled biodegradable peptide analog is a neurotensin, and
wherein the composition is a therapeutic or diagnostic compound.

### Claim 42 (depends on 41)

The composition of claim 41, wherein the NEP inhibitor comprises phosphoramidon or racecadotril.

### Claim 43 (depends on 41)

The composition of claim 41, wherein the composition further comprises an angiotensin-converting enzyme (ACE) inhibitor.

### Claim 44 (depends on 43)

The composition of claim 43, wherein the ACE inhibitor comprises lisinopril.

### Claim 45 (depends on 41)

The composition according to claim 41, wherein the radiolabeled biodegradable peptide analog is a radiometallated peptide-chelator conjugate or a peptide radiohalogenated via a prosthetic group.

### Claim 46 (depends on 41)

The composition according to claim 41, wherein the radiolabeled biodegradable peptide analog comprises a radioactive label selected from the group consisting of Tc, Re, In, Ga, Cu, F, I, Lu, Y, Bi, and Ac.

### Claim 47 (depends on 41)

The composition according to claim 41, wherein the radiolabeled biodegradable peptide analog comprises a radionuclide metal or halogen selected from the group comprising 111In, 99mTc, 94mTc, 67Ga, 66Ga, 68Ga, 52Fe, 69Er, 72As, 97Ru, 203Pb, 62Cu, 64Cu, 67Cu, 186Re, 188Re, 86Y, 90Y, 51Cr, 52mMn, 157Gd, 177Lu, 161Tb, 169Yb, 175Yb, 105Rh, 166Dy, 166Ho, 153Sm, 149Pm, 151Pm, 172Tm, 121Sn, 177mSn, 213Bi, 142Pr, 143Pr, 198Au, 199Au, 18F, 123I, 124I, 131I, 75Br, 76Br, 77Br, and 82Br.

### Claim 48 (depends on 41)

The composition of claim 41, wherein the composition comprises:
X-Demotensin 6 with a NEP inhibitor; or
X-Demotensin 1 with a NEP inhibitor and an ACE inhibitor,
wherein X is a radionuclide, and
wherein the composition is a therapeutic or diagnostic composition.

### Claim 49 (depends on 48)

The composition according to claim 48, wherein the composition comprises a combination selected from the group consisting of:
[99mTc]demotensin 6 with a NEP inhibitor; or
[99mTc]demotensin 1 with a NEP inhibitor and an ACE inhibitor;
wherein the composition is a therapeutic or diagnostic composition.

### Claim 50

A method of diagnosing cancer, the method comprising co-administering a radiolabeled biodegradable peptide analog with a neutral endopeptidase (NEP) inhibitor,
wherein the peptide-portion of the radiolabeled biodegradable peptide analog is a neurotensin, and
wherein the composition is a diagnostic compound.

### Claim 51 (depends on 50)

The method according to claim 50, wherein the neutral endopeptidase inhibitor comprises phosphoramidon or racecadotril.

### Claim 52 (depends on 50)

The method according to claim 50, wherein the administration of the radiolabeled biodegradable peptide analog is intravenous.

### Claim 53 (depends on 50)

The method according to claim 50, wherein the radiolabeled biodegradable peptide analog is a radiometallated peptide-chelator conjugate or a peptide modified with a prosthetic group for incorporation of radiohalogens.

### Claim 54 (depends on 50)

The method according to claim 50, wherein the radiolabeled biodegradable peptide analog comprises a radioactive label selected from the group consisting of Tc, Re, In, Ga, Cu, F, I, Lu, Y, Bi, and Ac.

### Claim 55 (depends on 50)

The method according to claim 50, wherein the radiolabeled biodegradable peptide analog comprises a radionuclide metal or halogen selected from the group comprising 111In, 99mTc, 94mTc, 67Ga, 66Ga, 68Ga, 52Fe, 69Er, 72As, 97Ru, 203Pb, 62Cu, 64Cu, 67Cu, 186Re, 188Re, 86Y, 90Y, 51Cr, 52mMn, 157Gd, 177Lu, 161Tb, 169Yb, 175Yb, 105Rh, 166Dy, 166Ho, 153Sm, 149Pm, 151Pm, 172Tm, 121Sn, 177mSn, 213Bi, 142Pr, 143Pr, 198Au, 199Au, 18F, 123I, 124I, 131I, 75Br, 76Br, 77Br, and 82Br.

### Claim 56 (depends on 50)

The method according to claim 50, wherein the co-administration comprises:
(i) administering the radiolabeled biodegradable peptide analog at the same time as the NEP inhibitor;
(ii) first administering the therapeutic radiolabeled biodegradable peptide analog, followed by administering the NEP inhibitor; or
(iii) first administering the NEP inhibitor, followed by administering the radiolabeled biodegradable peptide analog.

### Claim 57 (depends on 50)

The method according to claim 50, wherein the combination of a radiolabeled biodegradable peptide analog and a NEP inhibitor comprises X-Demotensin 6 with a neutral endopeptidase inhibitor;
wherein X is a radionuclide, and
wherein the composition is a diagnostic composition.

### Claim 58 (depends on 57)

The method according to claim 57, wherein the combination comprises [99mTc]demotensin 6 with a neutral endopeptidase inhibitor;
wherein the composition is a diagnostic composition.

### Claim 59 (depends on 50)

The method according to claim 50, wherein the method further comprises administering an angiotensin converting enzyme (ACE) inhibitor.

### Claim 60 (depends on 59)

The method according to claim 59, wherein the ACE inhibitor is lisinopril.

### Claim 61 (depends on 59)

The method according to claim 59, wherein the combination comprises X-Demotensin 1 with a NEP inhibitor and an ACE inhibitor,
wherein X is a radionuclide.

### Claim 62 (depends on 61)

The method according to claim 61, wherein the combination comprises [99mTc]demotensin 1 with a NEP inhibitor and an ACE inhibitor.

### Claim 63 (depends on 59)

The method according to claim 59, wherein the co-administration comprises:
(i) administering the radiolabeled biodegradable peptide analog at the same time as the NEP inhibitor and an ACE inhibitor;
(ii) first administering the therapeutic radiolabeled biodegradable peptide analog, followed by administering the NEP inhibitor and an ACE inhibitor; or
(iii) first administering the NEP inhibitor and an ACE inhibitor, followed by administering the radiolabeled biodegradable peptide analog.

### Claim 64 (depends on 59)

The method according to claim 59, wherein the ACE inhibitor is lisinopril.

### Claim 65

A method of treating cancer the method comprising co-administering a radiolabeled biodegradable peptide analog with a neutral endopeptidase (NEP) inhibitor,
wherein the peptide-portion of the radiolabeled biodegradable peptide analog is a neurotensin, and
wherein the composition is a therapeutic compound.

### Claim 66 (depends on 65)

The method according to claim 65, wherein the NEP inhibitor comprises phosphoramidon or racecadotril.

### Claim 67 (depends on 65)

The method according to claim 65, wherein the administration of the radiolabeled biodegradable peptide analog is intravenous.

### Claim 68 (depends on 65)

The method according to claim 65, wherein the radiolabeled biodegradable peptide analog is a radiometallated peptide-chelator conjugate or a peptide modified with a prosthetic group for incorporation of radiohalogens.

### Claim 69 (depends on 65)

The method according to claim 65, wherein the radiolabeled biodegradable peptide analog comprises a radioactive label selected from the group consisting of Tc, Re, In, Ga, Cu, F, I, Lu, Y, Bi, and Ac.

### Claim 70 (depends on 65)

The method according to claim 65, wherein the radiolabeled biodegradable peptide analog comprises a radionuclide metal or halogen selected from the group comprising 111In, 99mTc, 94mTc, 67Ga, 66Ga, 68Ga, 52Fe, 69Er, 72As, 97Ru, 203Pb, 62Cu, 64Cu, 67Cu, 186Re, 188Re, 86Y, 90Y, 51Cr, 52mMn, 157Gd, 177Lu, 161Tb, 169Yb, 175Yb, 105Rh, 166Dy, 166Ho, 153Sm, 149Pm, 151Pm, 172Tm, 121Sn, 177mSn, 213Bi, 142Pr, 143Pr, 198Au, 199Au, 18F, 123I, 124I, 131I, 75Br, 76Br, 77Br, and 82Br.

### Claim 71 (depends on 65)

The method according to claim 65, wherein the co-administration comprises:
(i) administering the radiolabeled biodegradable peptide analog at the same time as the NEP inhibitor;
(ii) first administering the therapeutic radiolabeled biodegradable peptide analog, followed by administering the NEP inhibitor; or
(iii) first administering NEP inhibitor, followed by administering the radiolabeled biodegradable peptide analog.

### Claim 72 (depends on 65)

The method according to claim 65, wherein the combination of a radiolabeled biodegradable peptide analog and a NEP inhibitor comprises X-Demotensin 6 with a NEP inhibitor,
wherein X is a radionuclide, and
wherein the composition is a therapeutic composition.

### Claim 73 (depends on 72)

The method according to claim 72, wherein the combination comprises [99mTc]demotensin 6 with a neutral endopeptidase inhibitor,
wherein the composition is a therapeutic composition.

### Claim 74 (depends on 65)

The method according to claim 65, wherein the method further comprises administering an angiotensin converting enzyme (ACE) inhibitor.

### Claim 75 (depends on 74)

The method according to claim 74, wherein the ACE inhibitor is lisinopril.

### Claim 76 (depends on 74)

The method according to claim 74, wherein the combination comprises X-Demotensin 1 with a NEP inhibitor and an ACE inhibitor,
wherein X is a radionuclide.

### Claim 77 (depends on 76)

The method according to claim 76, wherein the combination comprises [99mTc]demotensin 1 with a NEP inhibitor and an ACE inhibitor.

### Claim 78 (depends on 74)

The method according to claim 74, wherein the co-administration comprises:
(i) administering the radiolabeled biodegradable peptide analog at the same time as the NEP inhibitor and an ACE inhibitor;
(ii) first administering the therapeutic radiolabeled biodegradable peptide analog, followed by administering the NEP inhibitor and an ACE inhibitor; or
(iii) first administering the NEP inhibitor and an ACE inhibitor, followed by administering the radiolabeled biodegradable peptide analog.

### Claim 79 (depends on 78)

The method according to claim 78, wherein the ACE inhibitor is lisinopril.
